S
Sagent Pharmaceuticals
Developing, manufacturing, sourcing and marketing pharmaceutical products
About Sagent Pharmaceuticals
Sagent Pharmaceuticals is a company that specializes in the development, manufacturing, and marketing of injectable pharmaceutical products. The company operates in the healthcare and pharmaceutical market, primarily serving hospitals, clinics, and healthcare providers. Sagent's business model revolves around creating high-quality, safe, and reliable injectable medications, which are essential for various medical treatments and procedures. The company generates revenue by selling these pharmaceutical products to healthcare institutions and through strategic partnerships. Sagent places a strong emphasis on safety, as evidenced by their PreventIV Measures initiative, which aims to enhance patient safety through innovative packaging and labeling solutions. The company's product portfolio includes a wide range of injectable medications, such as Esmolol Hydrochloride Injection, Daptomycin for Injection, and Metronidazole Injection, USP. Sagent also engages in continuous product updates and recalls to ensure the highest standards of quality and safety. The company operates on a global scale, leveraging its expertise in pharmaceuticals to meet the needs of healthcare providers worldwide.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2007
- Headquarters
- Schaumburg, United States
- Employees
- 222
- Open positions
- None listed
- Dealroom signal
- 69.6/100
- Industry
- Health, Marketing
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jul 2016 | $736M | $736M | Undisclosed | — |
| IPOOther financing | Apr 2011 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Sagent Pharmaceuticals is 45K monthly website visits, up 28.6% over the last three months. Sagent Pharmaceuticals's team declined 8.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Capricorn Investment Group
Zhejiang Hisun Pharmaceutical
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sagent Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sagent Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.